A5056228251- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- CAR-T cell therapy research
- Monoclonal and Polyclonal Antibodies Research
- Virus-based gene therapy research
- Lipid metabolism and disorders
- interferon and immune responses
- Cholesterol and Lipid Metabolism
- Cancer Research and Treatments
- Galectins and Cancer Biology
Amsterdam University Medical Centers
2021-2025
University of Amsterdam
2022-2025
Institute of Infection and Immunity
2023
Abstract Autologous T-cell therapies show limited efficacy in chronic lymphocytic leukemia (CLL), where acquired immune dysfunction prevails. In CLL, disturbed mitochondrial metabolism has been linked to defective activation and proliferation. Recent research suggests that lipid regulates function differentiation T cells, yet its role CLL remains unexplored. This comprehensive study compares patients healthy donors, revealing critical dependence on exogenous cholesterol for human expansion...
Autologous T-cell-based therapies, such as chimeric antigen receptor (CAR) T-cell therapy, exhibit low success rates in chronic lymphocytic leukemia (CLL) and correlate with a dysfunctional phenotype observed patients. Despite various proposed mechanisms of dysfunction CLL, the specific CLL-derived factors responsible remain unidentified. This study aimed to investigate through which CLL cells suppress CAR activation function. We found that T get activated, albeit delayed fashion,...
Background Interferon (IFN)-β induction via activation of the stimulator interferon genes (STING) pathway has shown promising results in tumor models. STING is activated by cyclic dinucleotides such as GMP–AMP with phosphodiester linkages 2′–5′ and 3′–5′ (cGAMPs), that are produced synthetase (cGAS). However, delivery agonists to site a challenge. Bacterial vaccine strains have ability specifically colonize hypoxic tissues could therefore be modified overcome this Combining high...
T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. maturation antigen (BCMA) exhibits expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition γ-secretase. BCMA is considered a validated target in multiple myeloma but whether lymphomas targeted the BCMAxCD3 redirector teclistamab currently unknown. non-Hodgkin lymphoma primary chronic lymphocytic leukemia (CLL) was assessed flow cytometry...
<div><p>T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. maturation antigen (BCMA) exhibits expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition γ-secretase. BCMA is considered a validated target in multiple myeloma but whether lymphomas targeted the BCMAxCD3 T-cell redirector teclistamab currently unknown. non–Hodgkin lymphoma primary chronic lymphocytic leukemia (CLL) was...
<div><p>T-cell redirecting bispecific antibodies hold high promise for treatment of B-cell malignancies. maturation antigen (BCMA) exhibits expression on normal and malignant mature B cells including plasma cells, which can be enhanced by inhibition γ-secretase. BCMA is considered a validated target in multiple myeloma but whether lymphomas targeted the BCMAxCD3 T-cell redirector teclistamab currently unknown. non–Hodgkin lymphoma primary chronic lymphocytic leukemia (CLL) was...
Background: Chronic lymphocytic leukemia (CLL) remains incurable despite availability of targeted therapies. Successful autologous cell-based anti-cancer therapies require functionality and longevity effector cells, features that highly depend on complex metabolic processes. A key feature CLL is the suppression T-cell function, but underlying mechanism still poorly understood. We previously found signs impaired plasticity upon stimulation T cells from patients (van Bruggen, Blood 2019)....
Background: Waldenström's macroglobulinemia (WM) is an incurable low-grade B-cell Non-Hodgkin lymphoma. WM resembles chronic lymphocytic leukemia (CLL) with regard to biologic and clinical characteristics. In CLL, extensive abnormalities in T-cell subset distribution function have been described. These alterations may contribute disappointing responses directed immunotherapies. Novel autologous immunotherapy improve the outlook for patients. However, studies evaluating functionality are...